📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Century Therapeutics

1.1 - Company Overview

Century Therapeutics Logo

Century Therapeutics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of iPSC-derived allogeneic NK and T cell therapies for cancer and autoimmune diseases, including CNTY-101 targeting CD19-positive B-cell lymphomas (Phase 1 ELiPSE-1). Offers CRISPR-MAD7 mediated HDR gene editing, Allo-Evasion technology for immune evasion and repeat dosing, CAR and protein engineering, and common engineered iPSC progenitors to accelerate development.

Products and services

  • IPSC-derived NK and T cell therapies: Allogeneic, iPSC-based products built for hematological and solid cancers and autoimmune diseases, leveraging induced pluripotent stem cells to generate NK and T cell assemblies
  • Allo-Evasion™ technology: Custom-engineered system that enables cell therapy products to elude host immune surveillance, facilitating repeated dosing by reducing detection by the recipient immune system
  • CNTY-101: Clinical-stage cell therapy engineered to target CD19-positive B-cell lymphomas, currently under evaluation in the Phase 1 ELiPSE-1 clinical trial

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Century Therapeutics

Aadi Bioscience Logo

Aadi Bioscience

HQ: United States Website
  • Description: Provider of a potential mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Aadi Bioscience company profile →
Allorion Therapeutics Logo

Allorion Therapeutics

HQ: United States Website
  • Description: Provider of small-molecule therapeutics for cancer and autoimmune diseases, including an EGFR L858R allosteric inhibitor program to enhance existing treatments and prevent resistance; ARTS-021, an oral CDK2 inhibitor in Phase I/II for advanced/metastatic solid tumors; ARTS-011, a selective TYK2 inhibitor in early development; and high-throughput phenotypic screening to identify Werner Helicase inhibitors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Allorion Therapeutics company profile →
Medigene Logo

Medigene

HQ: Germany Website
  • Description: Provider of biotechnology solutions for cancer treatment, offering an end-to-end platform for developing TCR-guided therapies—including TCR-T, TCR-T cell engagers, and TCR-natural killer cell therapies—focused on specificity, sensitivity, and safety. Pipeline includes MDG1015 (NY-ESO-1/LAGE-1a, PD1-41BB) and MDG2011 (KRAS G12V, PD1-41BB) for solid tumors, plus 3S TCR technology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Medigene company profile →
Nuvectis Pharma Logo

Nuvectis Pharma

HQ: United States Website
  • Description: Provider of novel targeted cancer therapeutics, including NXP800, an oral small molecule activator of GCN2 in clinical trials for platinum-resistant, ARID1a-mutated ovarian cancer and cholangiocarcinoma, and NXP900, an oral small molecule inhibitor of SRC family kinases (SFK), including SRC and YES1, currently in a Phase 1 dose escalation clinical trial.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Nuvectis Pharma company profile →
Synta Pharmaceuticals Logo

Synta Pharmaceuticals

HQ: United States Website
  • Description: Provider of small molecule therapeutics to treat cancer and chronic inflammatory diseases, focused on the development and commercialization of these drugs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Synta Pharmaceuticals company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Century Therapeutics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Century Therapeutics

2.2 - Growth funds investing in similar companies to Century Therapeutics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Century Therapeutics

4.2 - Public trading comparable groups for Century Therapeutics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Century Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Century Therapeutics

What does Century Therapeutics do?

Century Therapeutics is a provider of iPSC-derived allogeneic NK and T cell therapies for cancer and autoimmune diseases, including CNTY-101 targeting CD19-positive B-cell lymphomas (Phase 1 ELiPSE-1). Offers CRISPR-MAD7 mediated HDR gene editing, Allo-Evasion technology for immune evasion and repeat dosing, CAR and protein engineering, and common engineered iPSC progenitors to accelerate development.

Who are Century Therapeutics's competitors?

Century Therapeutics's competitors and similar companies include Aadi Bioscience, Allorion Therapeutics, Medigene, Nuvectis Pharma, and Synta Pharmaceuticals.

Where is Century Therapeutics headquartered?

Century Therapeutics is headquartered in United States.

How many employees does Century Therapeutics have?

Century Therapeutics has 1,000 employees 🔒.

When was Century Therapeutics founded?

Century Therapeutics was founded in 2010 🔒.

What sector and industry vertical is Century Therapeutics in?

Century Therapeutics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Century Therapeutics

Who are the top strategic acquirers in Century Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in Century Therapeutics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Century Therapeutics?

Top strategic M&A buyers groups and sectors for Century Therapeutics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Century Therapeutics's sector and industry vertical

Which are the top PE firms investing in Century Therapeutics's sector and industry vertical?

Top PE firms investing in Century Therapeutics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Century Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Century Therapeutics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Century Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Century Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Century Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Century Therapeutics?

The key public trading comparables and valuation benchmarks for Century Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Century Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Century Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Century Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Century Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Century Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Century Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Century Therapeutics

Launch login modal Launch register modal